These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Engineering bispecificity into a single albumin-binding domain. Nilvebrant J; Alm T; Hober S; Löfblom J PLoS One; 2011; 6(10):e25791. PubMed ID: 21991353 [TBL] [Abstract][Full Text] [Related]
5. Engineered proteins as specific binding reagents. Binz HK; Plückthun A Curr Opin Biotechnol; 2005 Aug; 16(4):459-69. PubMed ID: 16005204 [TBL] [Abstract][Full Text] [Related]
6. Alternative non-antibody scaffolds for molecular recognition. Skerra A Curr Opin Biotechnol; 2007 Aug; 18(4):295-304. PubMed ID: 17643280 [TBL] [Abstract][Full Text] [Related]
7. Phage display for engineering and analyzing protein interaction interfaces. Sidhu SS; Koide S Curr Opin Struct Biol; 2007 Aug; 17(4):481-7. PubMed ID: 17870470 [TBL] [Abstract][Full Text] [Related]
8. Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein. Ebersbach H; Fiedler E; Scheuermann T; Fiedler M; Stubbs MT; Reimann C; Proetzel G; Rudolph R; Fiedler U J Mol Biol; 2007 Sep; 372(1):172-85. PubMed ID: 17628592 [TBL] [Abstract][Full Text] [Related]
9. Fully Human VH Single Domains That Rival the Stability and Cleft Recognition of Camelid Antibodies. Rouet R; Dudgeon K; Christie M; Langley D; Christ D J Biol Chem; 2015 May; 290(19):11905-17. PubMed ID: 25737448 [TBL] [Abstract][Full Text] [Related]
10. Replacing antibodies: engineering new binding proteins. Banta S; Dooley K; Shur O Annu Rev Biomed Eng; 2013; 15():93-113. PubMed ID: 23642248 [TBL] [Abstract][Full Text] [Related]
11. Molecular evolution of cystine-stabilized miniproteins as stable proteinaceous binders. Chang HJ; Hsu HJ; Chang CF; Peng HP; Sun YK; Yu HM; Shih HC; Song CY; Lin YT; Chen CC; Wang CH; Yang AS Structure; 2009 Apr; 17(4):620-31. PubMed ID: 19368895 [TBL] [Abstract][Full Text] [Related]
12. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2). Boshuizen RS; Marsden C; Turkstra J; Rossant CJ; Slootstra J; Copley C; Schwamborn K MAbs; 2014; 6(6):1415-24. PubMed ID: 25484047 [TBL] [Abstract][Full Text] [Related]
14. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Wu H; Nie Y; Huse WD; Watkins JD J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035 [TBL] [Abstract][Full Text] [Related]
15. Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. Chen W; Bardhi A; Feng Y; Wang Y; Qi Q; Li W; Zhu Z; Dyba MA; Ying T; Jiang S; Goldstein H; Dimitrov DS MAbs; 2016; 8(4):761-74. PubMed ID: 26963639 [TBL] [Abstract][Full Text] [Related]
16. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. Nygren PA FEBS J; 2008 Jun; 275(11):2668-76. PubMed ID: 18435759 [TBL] [Abstract][Full Text] [Related]
17. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent. Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285 [TBL] [Abstract][Full Text] [Related]
18. Humanization of antibodies. Almagro JC; Fransson J Front Biosci; 2008 Jan; 13():1619-33. PubMed ID: 17981654 [TBL] [Abstract][Full Text] [Related]
19. Expression, purification, and characterization of engineered antibody CH2 and VH domains. Gong R; Chen W; Dimitrov DS Methods Mol Biol; 2012; 899():85-102. PubMed ID: 22735948 [TBL] [Abstract][Full Text] [Related]
20. Design of phage-displayed cystine-stabilized mini-protein libraries for proteinaceous binder engineering. Chang HJ; Yang AS Methods Mol Biol; 2014; 1088():1-17. PubMed ID: 24146393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]